| Pair Name | Tanshinone IIA, Nutlin-3 | ||
| Phytochemical Name | Tanshinone IIA (PubChem CID: 164676 ) | ||
| Anticancer drug Name | Nutlin-3 (PubChem CID: 216345 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Tanshinone IIA, Nutlin-3 | |||
| Disease Info | [ICD-11: 2A60.Z] | Acute myeloid leukemia | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Down-regulation | Expression | MTOR | hsa2475 | |
| In Vitro Model | SUP-B15 | Childhood B acute lymphoblastic leukemia with t | Homo sapiens (Human) | CVCL_0103 |
| NALM-6 | Adult B acute lymphoblastic leukemia | Homo sapiens (Human) | CVCL_0092 | |
| HL-60 | Adult acute myeloid leukemia | Homo sapiens (Human) | CVCL_0002 | |
| MV4-11 | Childhood acute monocytic leukemia | Homo sapiens (Human) | CVCL_0064 | |
| Result | The results of this study demonstrate that the Nutlin-3 plus Tanshinone IIA combination exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways, although further investigation is warranted. Small-molecule MDM2 antagonists plus Tanshinone IIA may thus be a promising strategy for the treatment of acute leukemia. | |||
| No. | Title | Href |
|---|---|---|
| 1 | The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway. Int J Biochem Cell Biol. 2019 Jan;106:8-20. doi: 10.1016/j.biocel.2018.10.008. | Click |
